METHOCARBAMOL- methocarbamol tablet Oxford Pharmaceuticals, LLC


Methocarbamol Tablets, USP 500 mg Methocarbamol Tablets, USP 750 mg

Rx Only

DESCRIPTION

Methocarbamol Tablets, USP, 500 mg and 750 mg, a carbamate derivative of guaifenesin, is a central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties.

The chemical name of methocarbamol is 3-(2-methoxyphenoxy)-1, 2-propanediol 1carbamate and has the empirical formula $C_{11}H_{15}NO_5$. Its molecular weight is 241.24. The structural formula is shown below.



Methocarbamol is a white powder, sparingly soluble in water and chloroform, soluble in alcohol (only with heating) and propylene glycol, and insoluble in benzene and *n*-hexane.

Each tablet, for oral administration, contains either 500 mg or 750 mg of methocarbamol, USP. The inactive ingredients present are colloidal silicon dioxide, magnesium stearate, povidone, pregelatinized corn starch, purified water, sodium starch glycolate, and stearic acid.

CLINICAL PHARMACOLOGY

The mechanism of action of methocarbamol in humans has not been established, but may be due to general central nervous system (CNS) depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.

Pharmacokinetics

In healthy volunteers, the plasma clearance of methocarbamol ranges between 0.20 and 0.80 L/h/kg, the mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%.

Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of methocarbamol also is likely. Essentially all methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged methocarbamol also are excreted in the urine.

Special populations

Elderly

The mean (\pm SD) elimination half-life of methocarbamol in elderly healthy volunteers (mean [\pm SD] age, 69 [\pm 4] years) was slightly prolonged compared to a younger (mean [\pm SD] age, 53.3 [\pm 8.8] years), healthy population (1.5 [\pm 0.4] hours versus 1.1 [\pm 0.27] hours, respectively). The fraction of bound methocarbamol was slightly decreased in the elderly versus younger volunteers (41 to 43% versus 46 to 50%, respectively).

Renally impaired

The clearance of methocarbamol in 8 renally-impaired patients on maintenance hemodialysis was reduced about 40% compared to 17 normal subjects, although the mean (\pm SD) elimination half-life in these two groups was similar: 1.2 (\pm 0.6) versus 1.1 (\pm 0.3) hours, respectively.

Hepatically impaired

In 8 patients with cirrhosis secondary to alcohol abuse, the mean total clearance of methocarbamol was reduced approximately 70% compared to that obtained in 8 ageand weight-matched normal subjects. The mean (\pm SD) elimination half-life in the cirrhotic patients and the normal subjects was 3.38 (\pm 1.62) hours and 1.11 (\pm 0.27) hours, respectively. The percent of methocarbamol bound to plasma proteins was decreased to approximately 40 to 45% compared to 46 to 50% in the normal subjects.

INDICATIONS AND USAGE

Methocarbamol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties.

Methocarbamol does not directly relax tense skeletal muscles in man.

CONTRAINDICATIONS

Methocarbamol is contraindicated in patients hypersensitive to methocarbamol or to any of the tablet components.

WARNINGS

Since methocarbamol may possess a general CNS depressant effect, patients receiving methocarbamol tablets should be cautioned about combined effects with alcohol and other CNS depressants.

Safe use of methocarbamol has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, methocarbamol tablets should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see **PRECAUTIONS, Pregnancy**).

Use in Activities Requiring Mental Alertness

Methocarbamol may impair mental and/or physical abilities required for performance of

hazardous tasks, such as operating machinery or driving a motor vehicle. Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities.

PRECAUTIONS

Information for Patients

Patients should be cautioned that methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.

Because methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.

Drug Interactions

See WARNINGS and PRECAUTIONS for interaction with CNS drugs and alcohol.

Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore, methocarbamol should be used with caution in patients with myasthenia gravis receiving anticholinesterase agents.

Drug/Laboratory Test Interactions

Methocarbamol may cause a color interference in certain screening tests for 5hydroxyindoleacetic acid (5-HIAA) using nitrosonaphthol reagent and in screening tests for urinary vanillylmandelic acid (VMA) using the Gitlow method.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies to evaluate the carcinogenic potential of methocarbamol have not been performed. No studies have been conducted to assess the effect of methocarbamol on mutagenesis or its potential to impair fertility.

Pregnancy

Teratogenic Effects – Pregnancy Category C

Animal reproduction studies have not been conducted with methocarbamol. It is also not known whether methocarbamol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Methocarbamol should be given to a pregnant woman only if clearly needed.

Safe use of methocarbamol has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, methocarbamol should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see WARNINGS).

Nursing Mothers

Methocarbamol and/or its metabolites are excreted in the milk of dogs; however, it is not

known whether methocarbamol or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when methocarbamol is administered to a nursing woman.

Pediatric Use

Safety and effectiveness of methocarbamol in pediatric patients below the age of 16 have not been established.

ADVERSE REACTIONS

Adverse reactions reported coincident with the administration of methocarbamol include:

Body as a whole: Anaphylactic reaction, angioneurotic edema, fever, headache

Cardiovascular system: Bradycardia, flushing, hypotension, syncope, thrombophlebitis

Digestive system: Dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting

Hemic and lymphatic system: Leukopenia

Immune system: Hypersensitivity reactions

Nervous system: Amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo

Skin and special senses: Blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria

OVERDOSAGE

Limited information is available on the acute toxicity of methocarbamol. Overdose of methocarbamol is frequently in conjunction with alcohol or other CNS depressants and includes the following symptoms: nausea, drowsiness, blurred vision, hypotension, seizures, and coma.

In post-marketing experience, deaths have been reported with an overdose of methocarbamol alone or in the presence of other CNS depressants, alcohol or psychotropic drugs.

Treatment

Management of overdose includes symptomatic and supportive treatment. Supportive measures include maintenance of an adequate airway, monitoring urinary output and vital signs, and administration of intravenous fluids if necessary. The usefulness of hemodialysis in managing overdose is unknown.

DOSAGE AND ADMINISTRATION

Methocarbamol, 500 mg — Adults: Initial dosage: 3 tablets q.i.d. Maintenance dosage: 2 tablets q.i.d. Methocarbamol, 750 mg — Adults: Initial dosage: 2 tablets q.i.d. Maintenance dosage: 1 tablet q.4h. or 2 tablets t.i.d.

Six grams a day are recommended for the first 48 to 72 hours of treatment. (For severe conditions 8 grams a day may be administered). Thereafter, the dosage can usually be reduced to approximately 4 grams a day.

HOW SUPPLIED

Methocarbamol Tablets, USP 500 mg — white, round, convex face, debossed "611" over bisect and "O" below bisect on one side and plain on the reverse side. Available in:

Bottles of 90, NDC number 69584-611-09 bottles of 100, NDC number 69584-611-10 bottles of 500, NDC number 69584-611-50 bottles of 1000, NDC number 69584-611-90

Methocarbamol Tablets, USP 750 mg — white, capsule shape, convex face, debossed "612" on one side and debossed "O" on the reverse side. Available in:

bottles of 90, NDC number 69584-612-09 bottles of 100, NDC number 69584-612-10 bottles of 500, NDC number 69584-612-50 bottles of 1000, NDC number 69584-612-90

Store at 20° – 25°C (68° – 77°F) [See USP Controlled Room Temperature].

Dispense in tight container.

For more information, call Oxford Pharmaceuticals, LLC at 1-844-508-1455, 8:00 AM to 4.30 PM ET, Monday – Friday

Manufactured by: OXFORD PHARMACEUTICALS

Birmingham, AL 35211

8200004 Rev 12/20 R01

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 69584-611-10

METHOCARBAMOL TABLETS, USP 500 mg

Rx only 100 TABLETS

EACH TABLET CONTAINS:

Methocarbamol, USP ... 500 mg

DOSAGE: See package insert for full prescribing information.

DISPENSE in a tight container

STORE at 20 to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Manufactured by: OXFORD PHARMACEUTICALS, LLC BIRMINGHAM, AL 35211 8000021 Rev. 09/19 R01



NDC 69584-612-10

METHOCARBAMOL TABLETS, USP 750 mg

Rx only 100 TABLETS

EACH TABLET CONTAINS:

Methocarbamol, USP ... 750 mg

DOSAGE: See package insert for full prescribing information.

DISPENSE in a tight container

STORE at 20 to 25°C (68° to

77°F) [see USP Controlled Room Temperature].

Manufactured by: OXFORD PHARMACEUTICALS, LLC BIRMINGHAM, AL 35211 8000024 Rev. 09/19 R03



METHOCARBAMOL						
methocarbamol tablet						
Product Information						
Product Type	HUMAN PRESCRIPTION DRUG	ltem Co	de (Source)	NDC:	NDC:69584-611	
Route of Administration	ORAL					
Active Ingredient/Active	Molety					
Ingr	edient Name		Basis of Stre	ngth	Strength	
Methocarbamol (UNII: 1250D773		500 mg				
Inactive Ingredients						
mactive ingredients				-		
	Ingredient Name			S	trength	
Silicon Dioxide (UNII: ETJ7Z6XBL						
Magnesium Stearate (UNII: 700	97M6I30)					
Povidone K90 (UNII: RDH86HJV52	2)					
Starch, Corn (UNII: 08232NY3SJ)						
Water (UNII: 059QF0K00R)						
Sodium Starch Glycolate Type	A Potato (UNII: 5856J3G2A2)					
Stearic Acid (UNII: 4ELV7Z65AP)						

Product Characteristics						
Color	WHITE	Score	2 pieces			
Shape	ROUND	Size	13mm			
Flavor		Imprint Code	611;O			
Contains						

Packaging

#	ltem Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:69584-611- 09	90 in 1 BOTTLE; Type 0: Not a Combination Product	08/15/2019	
2	NDC:69584-611- 10	100 in 1 BOTTLE; Type 0: Not a Combination Product	08/15/2019	
3	NDC:69584-611- 50	500 in 1 BOTTLE; Type 0: Not a Combination Product	08/15/2019	
4	NDC:69584-611- 90	1000 in 1 BOTTLE; Type 0: Not a Combination Product	08/15/2019	
5	NDC:69584-611- 01	10 in 1 BOTTLE; Type 0: Not a Combination Product	08/15/2019	05/14/2021

Marketing Information

Marketing	Application Number or Monograph	Marketing Start	Marketing End
Category	Citation	Date	Date
ANDA	ANDA040489	08/15/2019	

METHOCARBAMOL

methocarbamol tablet

Product Information						
Product Type	NDC:	69584-612				
Route of Administration	on ORAL					
Active Ingredient/Active	Moiety					
ingr	ngth	Strength				
Methocarbamol (UNII: 1250D773		750 mg				
Inactive Ingredients						
Ingredient Name					trength	
Silicon Dioxide (UNII: ETJ7Z6XBL	14)					
Magnesium Stearate (UNII: 7009	97M6I30)					
Povidone K90 (UNII: RDH86HJV5Z	2)					
Starch, Corn (UNII: 08232NY3SJ)						
Water (UNII: 059QF0K00R)						

St	tearic Acid (UNII:	4ELV7Z6	5AP)					
_								
P	roduct Chara	acteris	tics					
С	olor		WHITE	Score			no score	
Sł	hape		CAPSULE	Size			19mm	
FI	avor			Imprint Co	de		612;O	
Co	ontains							
P	ackaging							
#	ltem Code		Package Description		r	Marketing Start Date	Marketing End Date	
1	NDC:69584-612- 09	90 in 1 E Product	BOTTLE; Type 0: Not a Combination		08/	/15/2019		
2	NDC:69584-612- 10	100 in 1 Product	BOTTLE; Type 0: Not a Combination		08/	/15/2019		
3	NDC:69584-612- 50	500 in 1 Product	1 BOTTLE; Type 0: Not a Combination ct		08/	/15/2019		
4	NDC:69584-612- 90	1000 in Product	1000 in 1 BOTTLE; Type 0: Not a Combination Product		08/15/2019			
5	NDC:69584-612- 01	10 in 1 BOTTLE; Type 0: Not a Combination Product		08/15/2019		05/14/2021		
M	1arketing	Inform	nation					
	Marketing Category	Ар		mber or Monograph itation	ו	Marketing Start Date	Marketing End Date	
	NDA		040489			08/15/2019		

Labeler - Oxford Pharmaceuticals, LLC (079638266)

Establishment							
Name	Address	ID/FEI	Business Operations				
Oxford Pharmaceuticals, LLC		079638266	manufacture(69584-611, 69584-612)				

Revised: 3/2024

Oxford Pharmaceuticals, LLC